Anadolu Ajansı Australia
Güvenilir haberin kaynağı. Anadolu Ajansı, Türkiye, dünya, ekonomi, spor, sağlık ve teknoloji alanlarındaki haberleri, fotoğraf ve videoları okurlara sunuyor.
Australia set for Chinese COVID-19 vaccine human trial - Anadolu Agency
Perth-based clinical research company begins to recruit healthy adults for trial - Anadolu Agency
ANKARA An Australian research and clinical facility is preparing to lunch human trial of COVID-19 vaccine developed by China, Chinese media reported on Tuesday. According to the state-run agency Xinhua, Linear Clinical Research, Perth-based clinical research company, has began to recruit healthy adults for the trial within next two months. S-Trimer vaccine, developed by China-based global biotechnology company Clover Biopharmaceuticals, is among the first COVID-19 vaccines under development. Linear also announced the vaccine trial on their website and called on the interested people to register with the company. "If you're healthy and located in Perth, WA, register your interest to participate in our upcoming COVID-19 vaccine study," the company said. Protein-based S-Trimer vaccine aims to help the body to produce anti-bodies to fight the virus, according to Xinhua. "This is one of the most prominent trials globally and involves some of the most renowned vaccine companies," the agency quoted Jayden Rogers, chief executive of Linear, as saying. S-Trimer vaccine on trial showed great potential and was at the forefront of the global battle with COVID-19, Rogers added. On April 14, Chinese authorities approved human testing of two other coronavirus vaccines developed by the Wuhan Institute of Biological Products under the China National Pharmaceutical Group (Sinopharm) and Sinovac Research and Development Co., Ltd, a company based in Beijing. Sinopharm has produced over 50,000 doses for the initial clinical trials. After production is normalized, the output could reach 3 million doses per batch with an annual output at 100 million doses, according to the Global Times, a Chinese state-run new outlet. The Chinese pharmaceutical group last week also extended offer for clinical trials of the COVID-19 vaccine in Pakistan, however Islamabad said they asked the company for more information. *Writing by Islamuddin Sajid Anadolu Agency website contains only a portion of the news stories offered to subscribers in the AA News Broadcasting System (HAS), and in summarized form. Please contact us for subscription options.
Anti-parasitic drug said to 'kill' COVID-19 cells - Anadolu Ajansı
Australia's Monash University needs funding to further research effectiveness, safety of drug against coronavirus - Anadolu Agency
ANKARA Scientists in Australia have found that an anti-parasitic drug available on the market “can kill” the growing cell culture of the deadly coronavirus within 48 hours. However, researchers say the drug cannot be used in humans for COVID-19 until further testing and clinical trials prove its safety and effectiveness. “Scientists showed that a single dose of the drug, Ivermectin, could stop the SARS-CoV-2 [COVID-19] virus growing in cell culture,” said a statement by Melbourne-based Monash University, where the research is based. “Scientists showed that a single dose of the drug, Ivermectin, could stop the SARS-CoV-2 virus growing in cell culture,” the statement said. “The potential use of Ivermectin to combat COVID-19 remains unproven, and depends on funding to progress the work into the next stages,” the statement added. Ivermectin has also been effective against HIV, dengue, influenza and the Zika virus. After originating in Wuhan, China last December, the novel coronavirus has spread to at least 184 countries and regions across the world, with its epicenter shifting to Europe from China. The virus has infected some 1.5 million people worldwide, while some 332,000 people recovered from the disease, according to data compiled by the U.S.' Johns Hopkins University. Nearly 90,000 have died. Anadolu Agency website contains only a portion of the news stories offered to subscribers in the AA News Broadcasting System (HAS), and in summarized form. Please contact us for subscription options.